应用MRI与镓-68 DOTATATE检测神经内分泌肿瘤肝转移
该单机构回顾性研究比较了MRI(DWI、DCE)与镓-68 DOTATATE PET/CT对神经内分泌肿瘤肝转移的检出率,共分析32例患者90个肝转移灶。结果显示MRI检出率高于镓-68 DOTATATE,DWI和DCE每检出1个镓-68 DOTATATE阳性病灶分别可检出1.28和1.33个病灶,作者建议NET分期时肝脏MRI应与镓-68 DOTATATE联合进行。
要点
- DWI和DCE对NET肝转移的检出率均高于镓-68 DOTATATE PET/CT。
- 每检出1个镓-68 DOTATATE阳性病灶,DWI可检出1.28个、DCE可检出1.33个病灶。
- NET分期时肝脏MRI应与镓-68 DOTATATE联合进行。
核心结论
- 与镓-68 DOTATATE相比,MRI可检出更多肝脏NET转移灶;NET分期时肝脏MRI应与镓-68 DOTATATE联合进行。
研究设计与样本
- IRB批准的单机构回顾性研究,纳入病理证实的NET患者32例(平均年龄59岁,男性59.4%),均于2017年3月至2020年2月间8周内接受镓-68 DOTATATE与MRI检查,分析90个肝转移灶。
诊断标准与关键数值
- 两名阅片者间ICC(95%CI):镓-68 DOTATATE为0.97(0.95,0.99),DWI为0.89(0.82,0.94),DCE为0.98(0.97,0.99)。
- 病灶匹配平均差异:DWI vs 镓-68 DOTATATE为+0.17±0.07(p=0.01),DCE vs 镓-68 DOTATATE为+0.22±0.06(p<0.001),均支持MRI。
- 基于病例的线性回归估计:每检出1个镓-68 DOTATATE病灶,DWI和DCE分别检出1.28(1.07,1.49)和1.33(1.12,1.54)个病灶。
临床应用与阅片要点
- NET分期时肝脏MRI应与镓-68 DOTATATE联合进行(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare detection rates of NET liver metastases of MRI and Ga-68-DOTATATE PET/CT to provide more clarity when selecting diagnostic imaging tests for NET staging.
METHODS: In this IRB-approved single-institution retrospective study, all patients with pathology-proven NET who underwent Ga-68-DOTATATE and MRI scans within 8 weeks of each other (3/2017-2/2020) were reviewed. Number of metastases for each patient on diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI, and Ga-68 DOTATATE were recorded by two blinded radiologists, followed by consensus review with two separate blinded readers for MRI and nuclear medicine. Per-lesion and -modality scoring at each lesion location were then performed in consensus. Per-patient linear regression was performed comparing MRI and Ga-68 DOTATATE detection rates for each reader and in consensus, and per-lesion-matched pair difference means were used to compare detection frequency between modalities.
RESULTS: 32 patients (mean age 59 years, 59.4% male) and 90 liver metastases were analyzed. Intraclass coefficients (ICC) [95% CI] between the two readers were 0.97 [0.95, 0.99], 0.89 [0.82, 0.94], and 0.98 [0.97, 0.99] for Ga-68 DOTATATE, DWI, and DCE, respectively. Matched per-lesion mean differences were + 0.17 ± 0.07 (p = 0.01) and + 0.22 ± 0.06 (p = < 0.001) for DWI versus Ga-68 DOTATATE and DCE vs Ga-68 DOTATATE, respectively, favoring MRI. Case-based linear regressions estimate that DWI and DCE detect 1.28 [1.07, 1.49] and 1.33 [1.12, 1.54] lesions, respectively, for each one detected on Ga-68 DOTATATE.
CONCLUSION: MRI detects more hepatic NET metastasis in comparison to Ga-68 DOTATATE. Liver MRI should be performed in concert with Ga-68 DOTATATE in NET staging.
引用
- Haider M, Jiang BG, Parker JA, et al. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases. Abdom Radiol (NY). 2021. PMID: 34757459. doi:10.1007/s00261-021-03341-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。